Purpose The ABDR is a clinical quality registry that was rolled out across Australia in 2015 with funding from the Commonwealth Department of Health. Over seven years it has provided a valuable resource to monitor the long-term safety and performance of breast implants, tissue expanders and matrix/mesh. Reports generated by the ABDR facilitate healthcare decision-making, industry based post-market surveillance and academic research. Methodology This presentation is based on the findings from the 2022 Annual Report, where the analysis is stratified by indication for surgery: cosmetic and reconstruction. It includes 87,339 patient records, employing descriptive statistics and time-to-revision analysis. Results The ABDR reported 100,114 procedures since 2012, with an overall device capture rate in 2022 of 76.3%. All cause revision rates for reconstructive post cancer procedures was 20% at 7 years, with revisions due to device malposition and capsular contracture being 5.7% and 5.9% respectively. Revision rates for post cancer reconstructive procedures have decreased from 3.8% in 2016 to 2.2% in 2022. All cause revision incidence rates for cosmetic implants at 7 years was 6.3%. The ABDR was notified of 5 cases of BIA-ALCL in this reporting period. Cases were most commonly reported 7-10 years post insertion, with the most common clinical issue associated being seroma/haematoma. Conclusions The ABDR has strong support amongst patients reflected in a consistently low opt-out rate of less than 1%. Surgeons are encouraged to report on their device revision and explantation procedures to ensure the ABDR is well placed to map device longevity and emerging trends in device related complications.